A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma—a common childhood tumor with a low survival rate.
Jun 25, 2020
0
6
Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital. They ...
Jun 19, 2020
0
1
Both the survival rate and the incidence of neuroblastoma have increased in recent years, as was shown by a study from the Princess Máxima Center. The improved chance of survival and the increase in the number of patients ...
Nov 18, 2019
0
3
(HealthDay)—Early treatment with an immune-boosting therapy might improve the outlook of young children with an advanced form of cancer, a new small study suggests.
Oct 10, 2019
0
31
Since the early 1990s, chemotherapy followed by an autologous stem cell transplant has been the standard of care for high-risk neuroblastoma, a childhood cancer that starts in nerve cells outside the brain, especially in ...
Sep 17, 2019
0
6
Researchers from Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania analyzed the largest cohort to date of pediatric patients with high-risk neuroblastoma treated ...
Apr 9, 2019
0
0
Neuroblastoma, a disease of immature nerve cells, is the most common solid tumor cancer occurring in children. About 700 new cases are diagnosed in the U.S. each year with approximately half of these children developing high-risk ...
Oct 4, 2018
0
0
A phase 2 clinical trial has found that combining a novel compound called alisertib with chemotherapy has anti-tumor activity in children with high-risk, relapsed neuroblastoma. The New Approaches to Neuroblastoma Therapy ...
Oct 1, 2018
0
48
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...
Jun 18, 2018
0
31
Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumour stroma reduces tumour ...
May 29, 2018
0
4
